Lunai Bioworks, Inc. LNAI 深 滬
等待開盤 03-26 09:30:00 美东时间
0.4015
+0.037
+10.00%
華盛通- 最 高0.4015
- 今 開0.3791
- 成交量 130.46万股
- 最 低 0.3527
- 昨 收 0.365
- 總市值 971.12万
- 52周最高 1.66
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.1214
- 委 比 -98.82%
- 總股本 2418.74万
- 歷史最高 13.78
- 量 比 0.06
- 振 幅 13.37%
- 歷史最低 0.1214
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lunai Bioworks Launches Pathfinder Consortium To Accelerate Chemical Antidote Development To 3-Year Timeline
AI platform integrates academic and defense research to accelerate rapid antidote discovery and federal stockpiling for emerging chemical threats.SACRAMENTO, Calif., March 19, 2026 /PRNewswire/ -- Lunai Bioworks
03-19 21:59
Why Playboy Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Playboy (PLBY) shares rise in pre-market trading after reporting better-than-expected Q4 results. Other gainers include PTOR, LNAI, LIDR, ISPC, WNW, JVA, NUAI, XLO, and BW. Losers include PRSO, DFLI, LNSR, and MVST.
03-18 00:19
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers AN2 Therapeutics (NASDAQ:ANTX) stock moved upwards by 94.4% to $5.54 d...
03-10 01:05
Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada On Feb 27, 2026
On February 27, 2026, Lunai Bioworks Inc. (the "Company") implemented a temporary furlough of its employees in the United States and Canada as part of actions intended to preserve the Company's liquidity while it
03-06 05:53
Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY
Lunai Bioworks Inc. - Common Stock (NASDAQ:LNAI) reported quarterly losses of $(0.08) per share. This is a 82.22 percent increase over losses of $(0.45) per share from the same period last year.
02-18 06:03
Lunai Bioworks Launches New Oncology Collaboration With Clinical-Stage Partner To Analyze Data From Randomized Phase 2 Metastatic Colorectal Cancer Trial
AI-driven analysis of Phase 2 survival and progression data aims to identify high-benefit patient subgroups and optimize future registrational trial strategySACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Lunai Bioworks
02-09 22:19
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
AI Platform Achieves Key Milestones, Triggering Launch of Alcohol Use Disorder Program SACRAMENTO, Calif. , Jan. 26, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug di...
01-26 22:30
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance
AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activity SACRAMENTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ: LNAI)...
2025-12-18 22:00
Lunai Bioworks Identifies Three Parkinson's Disease Subtypes And Drug Targets To Accelerate Therapeutic Development In $13B Market
Lunai Bioworks (NASDAQ:LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug
2025-12-09 20:50
Lunai Bioworks Secures First Letter Of Intent For Its Immune Cell Therapy
Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved
2025-11-25 20:46
